351 related articles for article (PubMed ID: 21684283)
1. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.
Tan IB; Ivanova T; Lim KH; Ong CW; Deng N; Lee J; Tan SH; Wu J; Lee MH; Ooi CH; Rha SY; Wong WK; Boussioutas A; Yeoh KG; So J; Yong WP; Tsuburaya A; Grabsch H; Toh HC; Rozen S; Cheong JH; Noh SH; Wan WK; Ajani JA; Lee JS; Tellez MS; Tan P
Gastroenterology; 2011 Aug; 141(2):476-85, 485.e1-11. PubMed ID: 21684283
[TBL] [Abstract][Full Text] [Related]
2. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
[TBL] [Abstract][Full Text] [Related]
3. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
[TBL] [Abstract][Full Text] [Related]
4. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer.
Kanda M; Oya H; Nomoto S; Takami H; Shimizu D; Hashimoto R; Sueoka S; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Dig Dis Sci; 2015 May; 60(5):1256-64. PubMed ID: 25487193
[TBL] [Abstract][Full Text] [Related]
5. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
Chen Y; Xia X; Wang S; Wu X; Zhang J; Zhou Y; Tan Y; He S; Qiang F; Li A; Røe OD; Zhou J
J Gastroenterol; 2013 Sep; 48(9):1034-44. PubMed ID: 23307041
[TBL] [Abstract][Full Text] [Related]
6. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
Galletti G; Zhang C; Gjyrezi A; Cleveland K; Zhang J; Powell S; Thakkar PV; Betel D; Shah MA; Giannakakou P
Clin Cancer Res; 2020 Jul; 26(14):3771-3783. PubMed ID: 32321717
[TBL] [Abstract][Full Text] [Related]
7. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy.
Jiang Y; Liu W; Li T; Hu Y; Chen S; Xi S; Wen Y; Huang L; Zhao L; Xiao C; Huang X; Han Z; Liu H; Qi X; Yang Y; Yu J; Cai S; Li G
EBioMedicine; 2017 Aug; 22():78-88. PubMed ID: 28687498
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
11. DNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy.
Teng KY; Qiu MZ; Li ZH; Luo HY; Zeng ZL; Luo RZ; Zhang HZ; Wang ZQ; Li YH; Xu RH
J Transl Med; 2010 Nov; 8():126. PubMed ID: 21110884
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Cunningham D; Starling N; Rao S; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR;
N Engl J Med; 2008 Jan; 358(1):36-46. PubMed ID: 18172173
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Song N; Pogue-Geile KL; Gavin PG; Yothers G; Kim SR; Johnson NL; Lipchik C; Allegra CJ; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S
JAMA Oncol; 2016 Sep; 2(9):1162-9. PubMed ID: 27270348
[TBL] [Abstract][Full Text] [Related]
14. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
[TBL] [Abstract][Full Text] [Related]
15. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer.
Cheong JH; Wang SC; Park S; Porembka MR; Christie AL; Kim H; Kim HS; Zhu H; Hyung WJ; Noh SH; Hu B; Hong C; Karalis JD; Kim IH; Lee SH; Hwang TH
Nat Commun; 2022 Feb; 13(1):774. PubMed ID: 35140202
[TBL] [Abstract][Full Text] [Related]
17. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Graves CA; Camphausen K; Kim HJ
Chemotherapy; 2012; 58(6):426-34. PubMed ID: 23295255
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
20. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
